Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS Combats Opioid Abuse By Blocking Prescriptions From Suspect Physicians

This article was originally published in The Pink Sheet Daily

Executive Summary

National pharmacy chain also advocates for national prescription drug monitoring database, mandatory e-prescribing for controlled substances. The Pharmaceutical Care Management Association offers legislators pharmacy-related policy recommendations to curb abuse.

You may also be interested in...



Rx Drug Abuse Monitoring Programs Could Require Prescriber Checks, Report Says

If adopted by states, the recommendation from the Brandeis white paper could add to the administrative burden for physicians who prescribe drugs with abuse potential, and thus create another sales and marketing challenge for sponsors.

Part D "Doctor Shopping": GAO's Remedies Find Little Buy-In From CMS

A Senate hearing examining the prevalence of “doctor shopping” by Medicare Part D enrollees revealed that CMS and the Government Accountability Office disagree on possible tools to address the issue, and perhaps more basically, who is responsible for implementing them.

Generic Substitution Of Controlled Drugs Allowed In DEA e-Prescribing Rule

The Drug Enforcement Administration says generic substitution of controlled substances will be allowed at the pharmacy level when the prescription is submitted electronically

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel